IPP Bureau
Leqembi wins NMPA nod for once-monthly IV dosing in early Alzheimer’s patients
By IPP Bureau - September 30, 2025
LEQEMBI was initially approved in China in January 2024 for the treatment of Alzheimer’s disease in patients with mild cognitive impairment
FDA authorizes first eyeglass lenses to slow progression of pediatric Myopia
By IPP Bureau - September 30, 2025
FDA authorization was based on two years of clinical study data demonstrating that Essilor Stellest lenses significantly slowed myopia progression compared to single-vision control lenses
AstraZeneca to launch DTC medication platform, offering up to 70% discounts on Farxiga, Airsupra
By IPP Bureau - September 30, 2025
The platform is being introduced to expand access to treatments for people living with chronic conditions
Revvity launches AI-powered software to transform preclinical imaging analysis
By IPP Bureau - September 30, 2025
The platform integrates artificial intelligence into a unified environment that supports optical, microCT, ultrasound, and other imaging modalities
Experts highlight critical link between mental well-being and cardiovascular health
By IPP Bureau - September 29, 2025
Health leaders rally for a national awakening on prevention, mental wellness, and lifestyle reform at ‘Illness to Wellness’ heart care conference
FDA approves Eli Lilly’s Inluriyo for adults with ER+, HER2-, ESR1-mutated advanced or metastatic breast cancer
By IPP Bureau - September 29, 2025
An estimated 50% of patients with ER+, HER2– metastatic breast cancer will develop an ESR1 mutation during or after exposure to an aromatase inhibitor
Moderna’s mNEXSPIKE generates strong immune response against LP.8.1 variant in humans
By IPP Bureau - September 29, 2025
Both of Moderna's COVID-19 vaccines for the 2025-2026 season have demonstrated strong immune responses against today's top circulating COVID-19 strains
Sanofi boosts Sanofi Ventures with additional $625 million September 24, 2025
By IPP Bureau - September 29, 2025
Sanofi Ventures drives innovation through leading and participating in private financing rounds for pioneering healthcare companies
AbbVie submits application to FDA for Tavapadon for treatment of Parkinson's disease
By IPP Bureau - September 29, 2025
If approved, tavapadon will enhance AbbVie's leadership in Parkinson's disease by providing patients with a once daily oral treatment option
Aptar Pharma opens new R&D center in France
By IPP Bureau - September 29, 2025
Expanded capabilities that continue to push the boundaries of innovation—advancing drug delivery solutions for patients, customers, and consumers around the world
Amgen invests $650 million on expansion of US manufacturing network
By IPP Bureau - September 29, 2025
Amgen has invested over $40 billion in manufacturing and research and development in US since 2017
Enhertu improved in invasive disease-free survival in early breast cancer in DB-05
By IPP Bureau - September 29, 2025
Second positive Phase III trial of AstraZeneca and Daiichi Sankyo’s Enhertu in HER2-positive early breast cancer reinforces its potential to become a foundational treatment option in curative-intent setting
AstraZeneca to harmonise its listing structure across LSE, STO and NYSE
By IPP Bureau - September 29, 2025
Harmonisation of listing structure requires a direct listing of AstraZeneca shares on the NYSE in place of existing US ADRs
European Commission approves Lilly’s Kisunla for treatment of early Alzheimer’s patients
By IPP Bureau - September 29, 2025
Cayman, Akadeum to revolutionize cell isolation for cell and gene therapy
By IPP Bureau - September 29, 2025
